Cleaning Validation during New Product Introduction in Shared Pharmaceutical Equipment: Development and Application of a Worst-Case Scenario Decision Framework

Abstract

Background: Multi-product pharmaceutical manufacturing facilities must ensure that the introduction of a
new product does not compromise an existing cleaning validation programme. However, regulatory guidance
documents provide no systematic, step-by-step framework for this new product introduction (NPI) stage
assessment.
Objectives: To develop a structured six-parameter worst-case scenario (WCS) assessment framework for
NPI-stage cleaning validation decisions and to validate the cleaning procedure for Sitagliptin as the identified
worst-case compound across three consecutive production batches.
Methods: A comparative six-parameter risk assessment was conducted between Sitagliptin 25/50/100 mg
film-coated tablets and the site's existing WCS product. Maximum allowable carryover (MAC) was calculated
using three methods (dose-based, 10 ppm, and PDE/HBEL-based). Swab and rinse sampling was performed
across a ten-equipment chain with a total product-contact surface area of 146,009.41 cm². Three consecutive
validation batches were executed after the manufacture of Sitagliptin 100 mg tablets.
Results: Sitagliptin was identified as the site WCS product based on a more stringent per-swab acceptance
limit of 1.59 ppm versus 11.2 ppm for the reference product, directly attributable to its larger equipment chain
surface area, not potency or solubility. All three validation batches passed all acceptance criteria. Total API
carryover was 15.22 mg, 17.24 mg, and 16.16 mg respectively (limit: NMT 150 mg), representing an ~88.5%
safety margin.
Conclusion: Equipment chain surface area — rather than potency alone — can be the decisive WCS
parameter during NPI. The proposed six-parameter framework provides a structured, reproducible, and
regulatorily compliant approach applicable to any multi-product OSD facility